TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution, To Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Pivot to Growth Strategy
Annual Report to Security Holders
Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
To Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Teva Extends Maturity Date of Revolving Credit Agreement to 2028
Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Teva's Q2 2025 Growth Fueled by Innovative Portfolio, Ups 2025 Revenue Outlook
Shareholder votes
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Free Writing Prospectus
Submission Upload
Correspondence